Month: May 2025

Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the first quarter of 2025. Cary Claiborne, CEO of Adial Pharmaceuticals, commented, “We made meaningful progress during the first quarter of 2025, completing foundational steps that position us to advance swiftly toward the initiation of our Phase 3 clinical trial for AD04, our lead investigational drug for Alcohol Use Disorder (AUD).” “One of the key achievements this quarter was the successful completion of our pharmacokinetics bridging study, AD04-103, which confirmed that AD04 delivers favorable...

Nuvini Group Completes Acquisition of B2B SaaS Platform Munddi

Written by Customer Service on May 15, 2025. Posted in Mergers And Acquisitions.

~ Successfully Marks the First of Four Anticipated Acquisitions in 2025 ~ ~ Creates New Synergies to Drive Revenue Growth and Enhance NVNI’s Ecosystem of B2B SaaS Solutions across Latin America ~ NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) — Nuvini Group Limited (Nasdaq: NVNI) (“Nuvini” or the “Company”), a leading acquirer of private B2B SaaS companies in Latin America, today announced that it has completed its previously announced acquisition of Munddi Soluções em Tecnologia Ltda. – ME (“Munddi”), an online platform that connects brands with consumers, suppliers, and retail chains based in São Paulo, Brazil. This successfully marks the first of four planned acquisitions in 2025 as part of Nuvini’s ongoing expansion strategy, creating new synergies to drive revenue growth and enhance its ecosystem of B2B solutions across Latin America. “We...

Innovative Food Holdings, Inc. Reports Financial Results for First Quarter of 2025

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

Key First Quarter data points:Revenue of $19.5 million, +26.0% vs. Q1 2024 Organic revenue growth (1) of +22.9% vs. Q1 2024 Gross margin declined by 157 basis points vs. Q1 2024 to 22.9% GAAP net income (loss) from continuing operations of ($0.4) million vs. $1.4 million in Q1 2024 GAAP net income (loss) from continuing operations per fully diluted share of ($0.008) vs. $0.028 in Q1 2024 Non-GAAP adjusted net income (loss) from continuing operations of $49 thousand vs. $161 thousand in Q1 2024 Non-GAAP adjusted net income (loss) per fully diluted share of $0.001 vs. $0.003 in Q1 2024 Non-GAAP adjusted EBITDA of $346 thousand vs. $486 thousand in Q1 2024 Announced new cheese business with an international airline, and relocated LoCo Foods business from Fort Collins to Denver New retail sales channel generated $3.7 million in revenue (1)...

Lifeward Ltd. Reports First Quarter 2025 Financial Results

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 15, 2025 (GLOBE NEWSWIRE) — Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments for LifewardLaunched the ReWalk 7, the newest generation of personal exoskeleton, in the U.S. market following FDA clearance in...

Bitcoin Depot Reports First Quarter 2025 Financial Results

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

Q1 Revenue up 19% Year-Over-Year to $164.2 Million Q1 Net Income up Significantly to $12.2 Million Compared to a Net Loss of $4.2 Million in the Prior Year Quarter Q1 Adjusted Gross Profit up 92% Year-Over-Year to $33.1 Million Q1 Adjusted EBITDA up 315% Year-Over-Year to $20.3 Million Q1 Cash from Operations of $16.3 Million ATLANTA, May 15, 2025 (GLOBE NEWSWIRE) — Bitcoin Depot Inc. (Nasdaq: BTM) (“Bitcoin Depot” or the “Company”), a U.S.-based Bitcoin ATM operator and leading fintech company, today reported financial results for the first quarter ended March 31, 2025. Bitcoin Depot will host a conference call and webcast at 10:00 a.m. ET today. An earnings presentation and link to the webcast will be made available at ir.bitcoindepot.com. “Bitcoin Depot delivered a remarkable first quarter, with 19% year-over-year revenue growth...

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

—Reported Positive 48-Week Data from SPRING Trial—Nebokitug Treatment in PSC Patients with Moderate/Advanced Disease Resulted in Continued Improvements across Key Biomarkers of Liver Injury, Inflammation and Fibrosis— —Aligned with FDA on Pathway to Potential Regulatory Approval for the Treatment of PSC with a Single, Clinical-Events-Driven Clinical Trial— —These Major Milestones Support the Advancement of Nebokitug to Phase 3 and Position It to Potentially Become the First FDA-Approved Treatment for PSC— —Cash Runway Extended to the Second Quarter of 2026— —Company Advancing Multiple Partnering Options for Executing the Nebokitug Program— TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd.(Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

NEW YORK and MELBOURNE, Australia, May 15, 2025 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing oral combination medicines, today reported fiscal second quarter financial results and provided business highlights for the quarter ended March 31, 2025. “The third quarter of 2025 represents a pivotal period of progress for Incannex as we continue to execute on our IHL-42X development program,” said Joel Latham, President and CEO of Incannex. “With the rapid completion of Phase 2 enrollment in the Phase 2/3 RePOSA, recent positive and confirmatory PK and safety clinical results, and the addition of expert sleep medicine clinical advisory leadership, we are well-positioned to deliver on key upcoming milestones and to advance IHL-42X as a...

AmpliTech Group Reports Q1 FY2025 Results and Signals Positive Outlook with Record Bookings and Strategic IP Advancements

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

Provides Full-Year Guidance Forecasting Over 100% Revenue Growth; Highlights Enhanced IP and Corporate Valuation HAUPPAUGE, N.Y., May 15, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW), a leader in the design and manufacture of advanced signal processing components for satellite, public and private 5G, and other communications systems, today reported its financial results for the first quarter ended March 31, 2025. Although Q1 results were not stellar, the company also shared encouraging revenue guidance for FY2025, driven by significant customer demand and the successful execution of IP-centered strategic initiatives. The company will host an investor call at 5:00 PM ET on Thursday, May 15, 2025.U.S. Toll-Free: 1-833-630-0019International Dial-In: 1-412-317-1807 Q1 FY2025 Highlights and Strategic ProgressRevenue...

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

NORCROSS, Ga., May 15, 2025 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2025. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, stated “This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week at the European Association for the Study of the Liver (EASL), specifically that we successfully demonstrated a clinically significant response in a key biomarker (Fibroscan®) that is used to support outcomes in MASH trials at every stage of disease progression. In December 2024, as part of the topline results from the NAVIGATE trial,...

Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update

Written by Customer Service on May 15, 2025. Posted in Earnings Releases And Operating Results.

ARVO presentation highlights 12-month results from Phase 1/2 study that support potential of OPGx-LCA5 gene therapy to restore meaningful vision Pediatric cohort of LCA5 study ongoing with initial multi-patient data anticipated in Q3 2025 OPGx-BEST1 on track for IND filing and initiation of Phase 1/2 trial with early data expected in Q1 2026 Leading healthcare investors provide funding to deliver on key milestones RESEARCH TRIANGLE PARK, N.C., May 15, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders (“Opus” or the “Company”), today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. “Opus is off...

Month: May 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals